Currently accepted at: JMIR Research Protocols
Date Submitted: Jul 28, 2025
Open Peer Review Period: Jul 29, 2025 - Sep 23, 2025
Date Accepted: Apr 3, 2026
(closed for review but you can still tweet)
This paper has been accepted and is currently in production.
It will appear shortly on 10.2196/81436
The final accepted version (not copyedited yet) is in this tab.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Contemporary Management of Isolated Iliac Aneurysms: Protocol for Systematic Review and Meta-analysis
ABSTRACT
Background:
Isolated iliac artery aneurysms (IIAAs) are uncommon, accounting for 2-7% of all abdominal arterial aneurysms. Historically, the mainstay of treatment had been open surgical repair (OSR), but recent advancements in endovascular interventions such as endovascular aneurysm repair (EVAR), iliac stent grafting, and embolisation techniques have improved clinical outcomes. However, there remains a need for clarity regarding the comparative effectiveness, risks, and long-term outcomes of different management approaches. This systematic review and meta-analysis aim to provide a comprehensive assessment of contemporary management strategies for IIAAs.
Objective:
This review aims to evaluate the current body of evidence on the 30-day major adverse cardiovascular events (MACE), aneurysm-related mortality, reintervention rate, long-term mortality, and length of hospital stay following endovascular repair and OSR.
Methods:
A literature search will be conducted in OVID Medline, EMBASE, SCOPUS, Cochrane Library, and ClinicalTrials.gov. Eligible studies include randomised and non-randomised controlled trials and observational studies. The primary outcome is 30-day major adverse cardiovascular events (MACE). The secondary outcomes are aneurysm-related mortality, reintervention rate, long-term mortality, and length of hospital stay. The Cochrane RoB2 tool for randomised controlled trials and Newcastle-Ottawa scale tool for observational trials will be used to assess bias. A meta-analysis of clinically homogenous studies will be performed using RevMan. A narrative systematic summary will be performed for data not amenable to meta-analysis.
Results:
Pilot work, formal searching, and study identification commenced on 23rd July 2025. Screening search results against inclusion and exclusion criteria is currently ongoing, which will be followed by data extraction, risk of bias and quality assessments, and data synthesis. We anticipate submitting the manuscript for peer review by the end of September 2025.
Conclusions:
This review will synthesise current evidence on the contemporary management strategies for IIAAs. Clinical Trial: PROSPERO CRD420250572416; https://www.crd.york.ac.uk/PROSPERO/view/CRD420250572416
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.